Kezar halts lupus trial after 4 deaths; IDMC recommends stop

Kezar Life Sciences, Inc.

Voluntary cessation of enrollment and dosing in PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis.
IDMC recommendation after review of 4 Grade 5 (fatal) serious adverse events in Philippines and Argentina.
Three fatalities showed common symptom pattern and proximity to dosing; additional non-fatal SAEs with similar pattern.
Kezar remains blinded to treatment arms; no prior deaths or serious opportunistic infections in earlier trials.
PORTOLA trial in autoimmune hepatitis continues enrollment; no Grade 4 or 5 SAEs observed there to date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.